Priti Manohar, MD
Neurology with Special Qualifications in Child Neurology · Edinburg, TXNPI 1336169945
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,293 of the $13,136 with a category attached, or 86.0%. It is spread thinly across 59 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,792 and has fallen 51.0% since, to $1,859 in 2025. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 613 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$3K
- UCB, Inc.$2K
- Neurelis, Inc.$732
- Neurocrine Biosciences, Inc.$581
- Cadwell Industries, Inc$550
- Teva Pharmaceuticals USA, Inc.$452
- plus $6K from 53 others
What the payments were for
- Consulting fees$1,80014%
- Food & beverage$11,29386%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$1,800
- Quillivant XR$161
How this compares
$13,136 in reported general payments places this provider in the 90th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $159,791 |
| NourianzIstradefylline | 21 | $51,976 |
| FycompaPerampanel | 38 | $47,955 |
| XcopriCenobamate | 37 | $42,878 |
| NeuproRotigotine | 31 | $36,268 |
| InbrijaLevodopa | 13 | $34,117 |
| AptiomEslicarbazepine Acetate | 25 | $29,982 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 122 | $26,816 |
| Memantine Hcl | 829 | $22,398 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $13,846 |
| Keppra XrLevetiracetam | 12 | $13,486 |
| Levetiracetam | 312 | $10,536 |
| ValtocoDiazepam | 14 | $10,167 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 353 | $5,380 |
| Quetiapine Fumarate | 315 | $5,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $452 | $159,79123 claims |
| Kyowa Kirin, Inc.Nourianz | $184 | $51,97621 claims |
| Eisai Inc.Fycompa | $428 | $47,95538 claims |
| SK Life Science, Inc.Xcopri | $2,544 | $42,87837 claims |
| UCB, Inc.Neupro | $1,922 | $36,26831 claims |
| Acorda Therapeutics, IncInbrija | $130 | $34,11713 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $405 | $29,98225 claims |
| Neurelis, Inc.Valtoco | $732 | $10,16714 claims |
| Upsher-smith Laboratories LLCTopiramate | $319 | $927115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
Other neurology with special qualifications in child neurology in Edinburg
- Wilson SyEdinburg$9K
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Michael PerryFort Worth$162K
- Raphael SchiffmannDallas$88K
- Mauricio Delgado-AyalaDallas$75K
- Kaitlin BatleyDallas$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.